Furthermore, an individual analysis of NSCLC patients revealed that multiple genes (validated METTTL1 and WDR4, as well as EIF4G1, SLBP, AGB2, EIF3D, and LSM1) might play important roles in NSCLC progression, which could serve as potential biomarkers for predicting patient prognosis and response to immunotherapy. This evidence concerns the gene EIF4G1 and non-small cell lung carcinoma.